Why AI matters at this scale

Moffitt Cancer Center is a premier, NCI-designated Comprehensive Cancer Center based in Tampa, Florida. Founded in 1986 and employing between 5,001-10,000 staff, it integrates cutting-edge research, clinical excellence, and community outreach to advance the prevention and cure of cancer. Its scale and mission position it as a national leader, handling a high volume of complex oncology cases and generating rich datasets from electronic health records (EHRs), genomic sequencing, clinical trials, and medical imaging.

For an organization of Moffitt's size and specialization, AI is not a distant future but a present imperative. The sheer volume and complexity of oncology data surpass human cognitive capacity for pattern recognition. AI and machine learning offer the tools to distill this data into actionable insights, transforming the paradigm from generalized protocols to truly personalized medicine. At this enterprise scale, the ROI from AI extends beyond clinical breakthroughs to significant operational efficiencies. Automating administrative burdens, optimizing resource utilization, and accelerating research can free substantial financial and human capital, which can be redirected to patient care and innovation, creating a sustainable competitive advantage in the highly specialized oncology market.

Concrete AI Opportunities with ROI Framing

First, AI-driven clinical decision support represents a high-impact opportunity. Deploying machine learning models that integrate genomic, proteomic, and imaging data to predict tumor behavior and treatment response can directly improve patient outcomes. The ROI is measured in extended survival, reduced recurrence, and avoidance of costly, ineffective therapies. For a center treating thousands of new patients annually, even marginal percentage improvements in response rates translate to immense clinical and economic value.

Second, operational intelligence through predictive analytics offers rapid, tangible returns. AI models forecasting patient admission rates, infusion chair demand, and surgical suite utilization allow for proactive staff scheduling and inventory management. This reduces overtime costs, minimizes expensive equipment idle time, and improves patient throughput. For an organization with an estimated annual revenue approaching $1.5 billion, optimizing capacity utilization by even a few percent can unlock tens of millions in operational savings annually.

Third, automating clinical trial matching addresses a critical bottleneck. Natural Language Processing (NLP) can scan EHRs in real-time to identify eligible patients for hundreds of active trials. This increases trial enrollment rates—a key metric for research funding—and gives patients faster access to novel therapies. The ROI includes enhanced research prestige, accelerated drug development timelines, and potential revenue from increased trial participation.

Deployment Risks Specific to This Size Band

Deploying AI at this scale introduces distinct challenges. Integration complexity is paramount; layering AI tools onto entrenched, enterprise-grade EHR systems like Epic or Cerner requires significant IT coordination and can create data silos if not managed holistically. Regulatory and compliance hurdles are magnified; any clinical AI application must navigate rigorous FDA clearance (if a device) and strict HIPAA adherence, requiring dedicated legal and compliance resources. Change management across 5,000+ employees, from oncologists to nurses to administrators, demands extensive training and clear communication to overcome skepticism and ensure adoption. Finally, model governance becomes critical; ensuring AI models are fair, unbiased, and explainable is essential for clinical trust and ethical care, necessitating robust MLOps frameworks that a smaller organization might avoid.